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Reply
We agree with Dr. Manev and colleagues that our study (1) does
not rule out the possibility that inflammatory pathways alternative
to those pertinent to the common biomarkers C-reactive protein
(CRP) and interleukin (IL)-6 may be involved in the link between
depression and cardiovascular disease (CVD). Depression is asso-
ciated with a number of inflammatory markers in addition to CRP
and IL-6, including, for example, IL-1 beta and tumor necrosis
factor alpha (2). The list may well include 5-lipoxygenase (5-
LOX), but unfortunately this has not yet been described, at least in
humans. C-reactive protein and IL-6 are the 2 biomarkers most
consistently associated with cardiovascular risk and therefore it
makes sense to begin with these as we try to disentangle the
complex link between depression, inflammation, and CVD. Be-
cause they are produced as part of the acute phase response, it is
possible that these common biomarkers are not truly biologic
markers for depression. On the other hand, inflammatory cyto-
kines have well-characterized effects in the central nervous system
that may influence depressive behavior, including effects on neu-
rotransmitter function and stimulation of the hypothalamus-
pituitary-adrenal axis (3). These actions suggest that inflammatory
processes are central to the pathogenesis of depression similar to
many other chronic conditions, such as CVD. It is also possible
that inflammation contributes to some, but not all, cases of
depression, as suggested by the wide range of inflammatory activity
commonly found in samples of depressed individuals. Thus,
subsets of individuals at the upper end of cytokine levels could
drive most of the association (4).
Dr. Manev and colleagues suggest a central role of an up-
regulated leukotriene synthesis pathway in the link between
depression and CVD. We agree with this possibility. A number of
genetic variations in the arachidonic acid cascade leading to
leukotriene synthesis have been linked to the risk of myocardial
infarction and increased carotid atherosclerosis (5–7). Unfortu-
nately, no data are yet available regarding the relationship between
5-LOX, or other components of this metabolic pathway, and
depression in humans. Until these data become available, this
biologic mechanism remains speculative.
We agree with Dr. Manev and colleagues that future studies
addressing the interconnections between depression, inflamma-
tion, and CVD should include a wider selection of inflammatory
markers that may be relevant to both atherosclerosis and depres-
sion; 5-LOX should be one of these. At the current stage of
knowledge, we believe that no inflammatory biomarker can be
credibly considered to be more than just a correlate of depression.
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Are Surrogate End
Points in Drug-Eluting
Stent Trials Reliable?
We read with great attention the paper by Pocock et al. (1). We
welcome their thorough analysis; however, we have a few concerns
related to some methodologic aspects of the manuscript.
The first relates to the assessment of treatment differences
among angiographic or clinical end point selected with the z-score.
We believe the authors should also report the rates of target lesion
revascularization (TLR) in the patients who were not supposed to
receive angiographic follow-up in the trials where a control
angiogram was mandated only in a subgroup of patients. This
would allow comparing the difference among stents (“delta”) in
TLR rate between the angiographic and the clinical cohorts and
indirectly comparing the “delta” in late loss (LL) and percentage
diameter stenosis (%DS) with the “delta” in TLR in the clinical
cohort. Indeed, despite the fact that the authors already acknowl-
edged in their discussion that systematic angiographic follow-up
can increase the rate of TLR, it would be useful to systematically
quantify this phenomenon and to observe if it can impact the
treatment differences between devices.
The second concern refers to the relationship between the size
of treatment effect on TLR and on LL/%DS, using the Hughes
criterion of surrogacy by visually plotting mean LL or %DS and
TLR rate. The authors should limit this analysis only to the
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